புகாரளித்தல் வழங்கியவர் தீனா பீஸ்லி திருத்துதல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from புகாரளித்தல் வழங்கியவர் தீனா பீஸ்லி திருத்துதல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In புகாரளித்தல் வழங்கியவர் தீனா பீஸ்லி திருத்துதல் Today - Breaking & Trending Today

German researchers tie cold viruses used to deliver COVID-19...


May 26 (Reuters) - German researchers on Wednesday said that based on laboratory research, they believed they have found the cause of the rare but serious blood clotting events among some people who received COVID-19 vaccines made by AstraZeneca Plc and Johnson & Johnson.
The researchers, in a study not yet reviewed by experts, said COVID-19 vaccines that employ adenovirus vectors - cold viruses used to deliver vaccine material - send some of their payload into the nucleus of cells, where some of the instructions for making coronavirus proteins can be misread. The resulting proteins could potentially trigger blood clot disorders in a small number of recipients, they suggest. ....

Pfizer Inc , University Of Frankfurt , Moderna Inc , Astrazeneca Plc , Reporting By Deena Beasley Editing , Bill Berkrot , ஃபைசர் இன்க் , பல்கலைக்கழகம் ஆஃப் பிராங்க்ஃபர்ட் , மாடர்னா இன்க் , புகாரளித்தல் வழங்கியவர் தீனா பீஸ்லி திருத்துதல் ,

Gilead 1st-quarter profit rises despite lower HIV drug sales


Gilead 1st-quarter profit rises despite lower HIV drug sales
Reuters
4/29/2021
April 29 (Reuters) - Gilead Sciences Inc on Thursday said its first-quarter product sales rose 16%, including $1.46 billion in sales of its COVID-19 antiviral drug remdesivir, but sales of flagship HIV and hepatitis C drugs were down due to the effects of the pandemic.
The biotech company reported adjusted earnings of $2.08 per share, edging out the average analyst estimate of $2.07 as compiled by Refinitiv. Net income rose to $1.72 billion from $1.54 billion.
The 16% rise in revenue for the quarter to $6.4 billion was still short of Wall Street estimates of $6.73 billion.
Gilead said the COVID-19 pandemic continued to hurt sales of its treatments for hepatitis C and HIV, due to fewer people going to their doctors during the pandemic. It now expects a more gradual recovery in the market starting in the current quarter. ....

United States , Deena Beasley , Gilead Sciences Inc On , Sciences Inc , Wall Street , Reporting By Deena Beasley Editing , Bill Berkrot , ஒன்றுபட்டது மாநிலங்களில் , தீனா பீஸ்லி , கிலியட் அறிவியல் இன்க் ஆன் , அறிவியல் இன்க் , சுவர் தெரு , புகாரளித்தல் வழங்கியவர் தீனா பீஸ்லி திருத்துதல் ,

Merck ends COVID-19 vaccine program, cites inferior immune responses


Drugmaker Merck & Co on Monday said it will end development of its two COVID-19 vaccines, and will focus pandemic research on treatments, with initial efficacy data on an experimental oral antiviral expected by the end of March.
Merck said in a statement it will record a pretax discontinuation charge in the fourth quarter for vaccine candidate V591, which it acquired with the purchase of Austrian vaccine maker Themis Bioscience, and V590, developed with nonprofit research organization IAVI.
In early trials, both vaccines generated immune responses that were inferior to those seen in people who had recovered from COVID-19 as well as those reported for other COVID-19 vaccines, the company said. ....

United States , Ridgeback Bio , Shri Navaratnam , Themis Bioscience , Pfizer Inc , Moderna Inc , Astrazeneca Plc , Drugmaker Merck Co On , Drugmaker Merck , Reporting By Deena Beasley Editing , ஒன்றுபட்டது மாநிலங்களில் , ரிட்ஜ்பேக் உயிர் , திரு நவரட்னம் , தீமிஸ் உயிர் அறிவியல் , ஃபைசர் இன்க் , மாடர்னா இன்க் , புகாரளித்தல் வழங்கியவர் தீனா பீஸ்லி திருத்துதல் ,

Merck ends COVID vaccine program, cites inferior immune responses


3 Min Read
Jan 25 (Reuters) - Drugmaker Merck & Co on Monday said it will end development of its two COVID-19 vaccines, and will focus pandemic research on treatments, with initial efficacy data on an experimental oral antiviral expected by the end of March.
Merck said in a statement it will record a pretax discontinuation charge in the fourth quarter for vaccine candidate V591, which it acquired with the purchase of Austrian vaccine maker Themis Bioscience, and V590, developed with nonprofit research organization IAVI.
In early trials, both vaccines generated immune responses that were inferior to those seen in people who had recovered from COVID-19 as well as those reported for other COVID-19 vaccines, the company said. ....

United States , Ridgeback Bio , Deena Beasley , Shri Navaratnam , Themis Bioscience , Thomson Reuters Trust Principles , Astrazeneca Plc , Drugmaker Merck Co On , Pfizer Inc , Moderna Inc , Reporting By Deena Beasley Editing , Thomson Reuters Trust , Coronavirus Merck , Corona Virus , Drug Amp Device Development , General News , General Health , Health Medicine , Healthcare Trbc Level 1 , Human Diseases Conditions , Infectious Diseases , North America , Pharmaceuticals Amp Medical Research Trbc Level 2 , Science Technology , ஒன்றுபட்டது மாநிலங்களில் , ரிட்ஜ்பேக் உயிர் ,